LEMAITRE VASCULAR INC (LMAT) Form 8-K — Nov 4, 2026
LeMaitre Vascular reported Q3 2026 sales of $68.0mm, up 11% (+12% organic), with grafts (+20%) and shunts (+14%) driving growth and adjusted EPS of $0.65 up 5% year-over-year. GAAP EPS of $0.65 was down 14% against a prior-year quarter inflated by an employee retention tax credit, while operating expenses rose 18% (adjusted). In October, the company acquired certain vascular assets from B. Braun for $19.2mm — grafts, valve cutters, and vein strippers with $9.4mm of 2025 sales — with sales transitioning into LeMaitre's channel over 18-24 months.
Key figures
- Eps
- 0.65
- Eps Beat
- adjusted EPS +5% YoY; GAAP EPS -14% YoY
- Revenue
- 67970000
- Guidance
- Q4 2026 sales $69.9-71.9mm (mid $70.9mm, +10%), EPS $0.70-0.75; FY2026 sales $274.8-276.8mm (mid $275.8mm, +11%), operating income $74.6-76.1mm, EPS $2.77-2.82 (mid $2.80, +11%, +18% adj.)
- Net Income
- 15024000
- Total Debt
- 169317000
- Revenue Yoy
- 11% (+12% organic)
- Total Assets
- 656032000
- Cash Position
- 390000000 total cash plus marketable securities ($27.5mm cash + $362.2mm short-term securities)
- Shares Outstanding
- 22,871 thousand basic weighted average
- Headcount
- 678 (+7%), sales reps 171 (+13%)
- Apac growth
- 5%
- Emea growth
- 18%
- Gross margin
- 71.7% (-360bps reported, +90bps adjusted)
- Americas growth
- 9%
- Operating income
- $17.7mm (-13% reported, +5% adjusted)
- Operating margin
- 26%
- Bbraun 2025 sales
- $9.4mm
- Dividend per share
- $0.25 quarterly
- Buyback authorization
- $100.0mm (concludes Feb 18, 2027)
- Bbraun acquisition price
- $19.2mm
- Organic growth composition
- 7% price, 5% units
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.